ERNA-201 / Ernexa Therapeutics - LARVOL DELTA

Following the encouraging ERNA-201 results, Ernexa has elected to pause additional preclinical development expenditures on ERNA-201 at this time and preserve the program while concentrating near-term resources on ERNA-101 and the expansion of its oncology pipeline (GlobeNewswire) - "The decision is a capital allocation priority rather than a scientific decision to discontinue ERNA-201. The Company believes the positive preliminary results provide a foundation from which ERNA-201 could potentially be advanced in the future as resources, strategic priorities and development opportunities warrant."

Pipeline update • Immunology • Inflammation

Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data… (GlobeNewswire) - "Mice treated with several ERNA-201 lead candidates demonstrated reductions in disease severity relative to untreated controls, including improvements in clinical arthritis scores. Ernexa believes the findings are consistent with the candidate's intended anti-inflammatory mechanism and provide meaningful proof-of-concept support for the use of synthetic, cytokine-engineered iMSCs in inflammatory and autoimmune disease."

Preclinical • Immunology • Inflammation • Inflammatory Arthritis

Development Program Highlights: ERNA-201 (GlobeNewswire) - "Anticipated a pre-IND meeting to obtain regulatory alignment by Q1 2026."

FDA event • Rheumatoid Arthritis